Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Jul;31(7):971–977. doi: 10.1128/aac.31.7.971

Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy.

J W Hathorn 1, M Rubin 1, P A Pizzo 1
PMCID: PMC174854  PMID: 3310871

Full text

PDF
971

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alanis A., Rehm S., Weinstein A. J. Comparative efficacy and toxicity of moxalactam and the combination of nafcillin and tobramycin in febrile granulocytopenic patients. Cleve Clin Q. 1983 Winter;50(4):385–395. doi: 10.3949/ccjm.50.4.385. [DOI] [PubMed] [Google Scholar]
  2. Anderson E. T., Young L. S., Hewitt W. L. Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy. 1978;24(1):45–54. doi: 10.1159/000237759. [DOI] [PubMed] [Google Scholar]
  3. Barriere S. L., Flaherty J. F. Third-generation cephalosporins: a critical evaluation. Clin Pharm. 1984 Jul-Aug;3(4):351–373. [PubMed] [Google Scholar]
  4. Berger S. A. The use of antimicrobial agents for noninfectious diseases. Rev Infect Dis. 1985 May-Jun;7(3):357–367. doi: 10.1093/clinids/7.3.357. [DOI] [PubMed] [Google Scholar]
  5. Bodey G. P., Buckley M., Sathe Y. S., Freireich E. J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966 Feb;64(2):328–340. doi: 10.7326/0003-4819-64-2-328. [DOI] [PubMed] [Google Scholar]
  6. Bodey G. P., Middleman E., Umsawadi T., Rodriguez V. Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer. 1972 Jun;29(6):1697–1701. doi: 10.1002/1097-0142(197206)29:6<1697::aid-cncr2820290638>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  7. Bodey G. P., Whitecar J. P., Jr, Middleman E., Rodriguez V. Carbenicillin therapy for pseudomonas infections. JAMA. 1971 Oct 4;218(1):62–66. [PubMed] [Google Scholar]
  8. Bryant R. E., Hood A. F., Hood C. E., Koenig M. G. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med. 1971 Jan;127(1):120–128. [PubMed] [Google Scholar]
  9. Darbyshire P. J., Williamson P. J., Pedler S. J., Speller D. C., Mott M. G., Oakhill A. Ceftazidime in the treatment of febrile immunosuppressed children. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):357–360. doi: 10.1093/jac/12.suppl_a.357. [DOI] [PubMed] [Google Scholar]
  10. Drusano G. L., Schimpff S. C., Hewitt W. L. The acylampicillins: mezlocillin, piperacillin, and azlocillin. Rev Infect Dis. 1984 Jan-Feb;6(1):13–32. doi: 10.1093/clinids/6.1.13. [DOI] [PubMed] [Google Scholar]
  11. Fainstein V., Bodey G. P., Elting L., Bolivar R., Keating M. J., McCredie K. B., Valdivieso M. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):101–110. doi: 10.1093/jac/12.suppl_a.101. [DOI] [PubMed] [Google Scholar]
  12. Feld R., Valdivieso M., Bodey G. P., Rodriguez V. Comparison of amikacin and tobramycin in the treatment of infection in patients with cancer. J Infect Dis. 1977 Jan;135(1):61–66. doi: 10.1093/infdis/135.1.61. [DOI] [PubMed] [Google Scholar]
  13. Freid M. A., Vosti K. L. The importance of underlying disease in patients with gram-negative bacteremia. Arch Intern Med. 1968 May;121(5):418–423. [PubMed] [Google Scholar]
  14. Friis H., Hoffmann S., Hansen M., Hansen M. M., Justesen T., Nissen N. I. Cefotaxime versus ampicillin, methicillin and netilmicin in combination for treatment of febrile episodes in patients with haematologic malignancy. Acta Med Scand. 1983;213(5):345–349. doi: 10.1111/j.0954-6820.1983.tb03749.x. [DOI] [PubMed] [Google Scholar]
  15. Fu K. P., Neu H. C. Azlocillin and mezlocillin: new ureido penicillins. Antimicrob Agents Chemother. 1978 Jun;13(6):930–938. doi: 10.1128/aac.13.6.930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hathorn J. W., Pizzo P. A. Is there a role for monotherapy with beta-lactam antibiotics in the initial empirical management of febrile neutropenic cancer patients? J Antimicrob Chemother. 1986 Mar;17 (Suppl A):41–54. doi: 10.1093/jac/17.suppl_a.41. [DOI] [PubMed] [Google Scholar]
  17. Issell B. F., Bodey G. P. Mezlocillin for treatment of infections in cancer patients. Antimicrob Agents Chemother. 1980 Jun;17(6):1008–1013. doi: 10.1128/aac.17.6.1008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Jawetz E. The use of combinations of antimicrobial drugs. Annu Rev Pharmacol. 1968;8:151–170. doi: 10.1146/annurev.pa.08.040168.001055. [DOI] [PubMed] [Google Scholar]
  19. Karp J. E., Dick J. D., Angelopulos C., Charache P., Green L., Burke P. J., Saral R. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med. 1986 Aug;81(2):237–242. doi: 10.1016/0002-9343(86)90257-3. [DOI] [PubMed] [Google Scholar]
  20. Klastersky J., Cappel R., Daneau D. Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob Agents Chemother. 1972 Dec;2(6):470–475. doi: 10.1128/aac.2.6.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Klastersky J., Cappel R., Daneau D. Therapy with carbenicillin and gentamicin for patients with cancer and severe infections caused by gram-negative rods. Cancer. 1973 Feb;31(2):331–336. doi: 10.1002/1097-0142(197302)31:2<331::aid-cncr2820310210>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  22. Klastersky J., Zinner S. H. Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis. 1982 Mar-Apr;4(2):294–301. doi: 10.1093/clinids/4.2.294. [DOI] [PubMed] [Google Scholar]
  23. Kluge R. M., Standiford H. C., Tatem B., Young V. M., Greene W. H., Schimpff S. C., Calia F. M., Hornick R. B. Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1974 Oct;6(4):442–446. doi: 10.1128/aac.6.4.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kluge R. M., Standiford H. C., Tatem B., Young V. M., Schimpff S. C., Greene W. H., Calia F. M., Hornick R. B. The carbenicillin-gentamicin combination against Pseudomonas aeruginosa. Correlation of effect with gentamicin sensitivity. Ann Intern Med. 1974 Nov;81(5):584–587. doi: 10.7326/0003-4819-81-5-584. [DOI] [PubMed] [Google Scholar]
  25. Kramer B. S., Ramphal R., Rand K. H. Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients. Antimicrob Agents Chemother. 1986 Jul;30(1):64–68. doi: 10.1128/aac.30.1.64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lawson R. D., Baskin R. C. Ceftizoxime treatment of infection in neutropenic patients with malignancies. J Antimicrob Chemother. 1982 Nov;10 (Suppl 100):159–165. doi: 10.1093/jac/10.suppl_c.159. [DOI] [PubMed] [Google Scholar]
  27. Levine A. S., Schimpff S. C., Graw R. G., Jr, Young R. C. Hematologic malignancies and other marrow failure states: progress in the management of complicating infections. Semin Hematol. 1974 Apr;11(2):141–202. [PubMed] [Google Scholar]
  28. McGowan J. E., Jr, Barnes M. W., Finland M. Bacteremia at Boston City Hospital: Occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. J Infect Dis. 1975 Sep;132(3):316–335. doi: 10.1093/infdis/132.3.316. [DOI] [PubMed] [Google Scholar]
  29. Middleman E. L., Watanabe A., Kaizer H., Bodey G. P. Antibiotic combinations for infections in neutropenic patients. Evaluaton of carbenicillin plus either cephalothin or kanamycin. Cancer. 1972 Aug;30(2):573–579. doi: 10.1002/1097-0142(197208)30:2<573::aid-cncr2820300238>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  30. Morgan G., Duerden B. I., Lilleyman J. S. Ceftazidime as a single agent in the management of children with fever and neutropenia. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):347–351. doi: 10.1093/jac/12.suppl_a.347. [DOI] [PubMed] [Google Scholar]
  31. Neu H. C. The new beta-lactamase-stable cephalosporins. Ann Intern Med. 1982 Sep;97(3):408–419. doi: 10.7326/0003-4819-97-3-408. [DOI] [PubMed] [Google Scholar]
  32. Piccart M., Klastersky J., Meunier F., Lagast H., Van Laethem Y., Weerts D. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother. 1984 Dec;26(6):870–875. doi: 10.1128/aac.26.6.870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Pizzo P. A., Hathorn J. W., Hiemenz J., Browne M., Commers J., Cotton D., Gress J., Longo D., Marshall D., McKnight J. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986 Aug 28;315(9):552–558. doi: 10.1056/NEJM198608283150905. [DOI] [PubMed] [Google Scholar]
  34. Pizzo P. A., Ladisch S., Simon R. M., Gill F., Levine A. S. Increasing incidence of Gram-positive sepsis in cancer patients. Med Pediatr Oncol. 1978;5(1):241–244. doi: 10.1002/mpo.2950050133. [DOI] [PubMed] [Google Scholar]
  35. Pizzo P. A., Robichaud K. J., Gill F. A., Witebsky F. G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982 Jan;72(1):101–111. doi: 10.1016/0002-9343(82)90594-0. [DOI] [PubMed] [Google Scholar]
  36. Ramphal R., Kramer B. S., Rand K. H., Weiner R. S., Shands J. W., Jr Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):81–88. doi: 10.1093/jac/12.suppl_a.81. [DOI] [PubMed] [Google Scholar]
  37. Reilly J. T., Brada M., Bellingham A. J., Hart C. A., Bennet C. Ceftazidime compared to tobramycin and ticarcillin in immunocompromised haematological patients. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):89–92. doi: 10.1093/jac/12.suppl_a.89. [DOI] [PubMed] [Google Scholar]
  38. Reyes M. P., El-Khatib M. R., Brown W. J., Smith F., Lerner A. M. Synergy between carbenicillin and an aminoglycoside (gentamicin or tobramycin) against Pseudomonas aeruginosa isolated from patients with endocarditis and sensitivity of isolates to normal human serum. J Infect Dis. 1979 Aug;140(2):192–202. doi: 10.1093/infdis/140.2.192. [DOI] [PubMed] [Google Scholar]
  39. Riff L. J., Jackson G. G. Pharmacology of gentamicin in man. J Infect Dis. 1971 Dec;124 (Suppl):S98–105. doi: 10.1093/infdis/124.supplement_1.s98. [DOI] [PubMed] [Google Scholar]
  40. Rodriguez V., Bodey G. P., Horikoshi N., Inagaki J., McCredie K. B. Ticarcillin therapy of infections. Antimicrob Agents Chemother. 1973 Oct;4(4):427–431. doi: 10.1128/aac.4.4.427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Schimpff S., Satterlee W., Young V. M., Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971 May 13;284(19):1061–1065. doi: 10.1056/NEJM197105132841904. [DOI] [PubMed] [Google Scholar]
  42. Umsawasdi T., Middleman E. A., Luna M., Bodey G. P. Klebsiella bacteremia in cancer patients. Am J Med Sci. 1973 Jun;265(6):473–482. doi: 10.1097/00000441-197306000-00006. [DOI] [PubMed] [Google Scholar]
  43. Valdivieso M., Feld R., Rodriguez V., Bodey G. P. Amikacin therapy of infections in neutropenic patients. Am J Med Sci. 1975 Nov-Dec;270(3):453–463. doi: 10.1097/00000441-197511000-00006. [DOI] [PubMed] [Google Scholar]
  44. Valdivieso M., Horikoshi N., Rodriguez V., Bodey G. P. Therapeutic trials with tobramycin. Am J Med Sci. 1974 Sep;268(3):149–156. doi: 10.1097/00000441-197409000-00003. [DOI] [PubMed] [Google Scholar]
  45. Van Laethem Y., Lagast H., Klastersky J. Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae. Antimicrob Agents Chemother. 1983 Mar;23(3):435–439. doi: 10.1128/aac.23.3.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Wade J. C., Schimpff S. C., Newman K. A., Fortner C. L., Moody M. R., Young V. M., Wiernik P. H. Potential of mezlocillin as empiric single-agent therapy in febrile granulocytopenic cancer patients. Antimicrob Agents Chemother. 1980 Aug;18(2):299–306. doi: 10.1128/aac.18.2.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Wade J. C., Schimpff S. C., Newman K. A., Fortner C. L., Standiford H. C., Wiernik P. H. Piperacillin or ticarcillin plus amikacin. A double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med. 1981 Dec;71(6):983–990. doi: 10.1016/0002-9343(81)90324-7. [DOI] [PubMed] [Google Scholar]
  48. Wade J. C., Schimpff S. C., Newman K. A., Wiernik P. H. Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med. 1982 Oct;97(4):503–508. doi: 10.7326/0003-4819-97-4-503. [DOI] [PubMed] [Google Scholar]
  49. Wade J. C., Standiford H. C., Drusano G. L., Johnson D. E., Moody M. R., Bustamante C. I., Joshi J. H., deJongh C., Schimpff S. C. Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer. Am J Med. 1985 Jun 7;78(6A):62–72. doi: 10.1016/0002-9343(85)90103-2. [DOI] [PubMed] [Google Scholar]
  50. Whitecar J. P., Jr, Luna M., Bodey G. P. Pseudomonas bacteremia in patients with malignant diseases. Am J Med Sci. 1970 Oct;60(4):216–223. doi: 10.1097/00000441-197010000-00003. [DOI] [PubMed] [Google Scholar]
  51. Winston D. J., Dudnick D. V., Chapin M., Ho W. G., Gale R. P., Martin W. J. Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy. Arch Intern Med. 1983 Jan;143(1):32–36. [PubMed] [Google Scholar]
  52. Winston D. J., McGrattan M. A., Busuttil R. W. Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections. Antimicrob Agents Chemother. 1984 Nov;26(5):673–677. doi: 10.1128/aac.26.5.673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Young L. S., Martin W. J., Meyer R. D., Weinstein R. J., Anderson E. T. Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations. Ann Intern Med. 1977 Apr;86(4):456–471. doi: 10.7326/0003-4819-86-4-456. [DOI] [PubMed] [Google Scholar]
  54. de Pauw B. E., Kauw F., Muytjens H., Williams K. J., Bothof T. Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):93–99. doi: 10.1093/jac/12.suppl_a.93. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES